Immune Modulators Gastrointestinal Peptides Under research

Larazotide

Also known as: Larazotide Acetate, AT-1001, INN-202

Larazotide acetate is an eight-amino acid peptide (octapeptide) that has been extensively researched as a treatment for celiac disease and intestinal permeability ("leaky gut"). It acts locally in the small intestine restoring the barrier function of tight junctions between intestinal cells, preventing toxins and antigens (like gluten) from crossing into the bloodstream.

Mechanism of action

Acts as a regulator of the zonulin protein, which controls the opening and closing of tight junctions.
Reduces the gluten/gliadin-induced opening of intercellular junctions.
It remains and acts in the lumen of the gastrointestinal tract; systemic absorption is minimal, contributing to its safety.

Uses & indications

Celiac Disease: Reduction of symptoms during accidental gluten exposure.
Leaky gut syndrome: Restoration of the intestinal barrier.
Autoimmune conditions: Preventing the passage of antigens that trigger autoimmune responses.

Effects

Significant improvement of gastrointestinal symptoms in celiacs and patients with leaky gut, reduction of inflammation mediated by the passage of pathogens.

Considerations & contraindications

Taken orally before meals, no injection required.
Does not cure celiac disease or allow for abandoning a gluten-free diet, but protects against cross-contamination.

Regulatory approval

Reached Phase 3 clinical trials, being one of the most advanced drugs in development for celiac disease.

Dosage

Typically researched in doses of 0.5mg to 2mg taken orally three times a day prior to meals.

Storage

Store in a cool, dry place away from direct light.

Technical data

Regulatory status Under research

Molecular weight 824.9 Da

Half-life Actúa localmente en el tracto GI

Administration routes Oral (Cápsulas gastroresistentes)